5
Feb
2015

Former Dendreon CEO Lures Ex-Amgen Scientists to Immunotherapy Startup

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

A Trek in the Himalayas for Cancer Research
ADCs: If at First You Don’t Succeed…
When Raising Drug Prices Helps Patients
A Busy IPO Calendar: Forma, Repare, Progenity, Genetron